Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Narcolepsy is more than falling asleep at the wrong time: it is a chronic sleep disorder that can affect daytime alertness, muscle tone, nighttime sleep and the transitions between sleeping and waking. A new U.S. approval marks a significant change in treatment for adults with narcolepsy type 1, but it is not a cure and does not apply to every type of narcolepsy.
This article explains the condition and the approval discussed in The Guardian’s Science Weekly episode published 6 October 2026. The episode listing says Madeleine Finlay discusses the FDA approval with Ian Sample, alongside Julie Flygare, a person with narcolepsy and founder of Project Sleep. The listing is a synopsis, not a transcript, so it does not establish the guests’ detailed wording or personal testimony. The Guardian episode listing on Apple Podcasts and The Guardian’s audio index identify the episode and its publication date.
As an Amazon Associate I earn from qualifying purchases.
What is narcolepsy?
Narcolepsy is a long-term neurological sleep disorder. Its symptoms differ from person to person and may include excessive daytime sleepiness, disrupted nighttime sleep, sleep paralysis, vivid hallucinations as someone falls asleep or wakes, and cataplexy. Cataplexy is a sudden loss of muscle tone, often triggered by strong emotions; it can range from brief weakness to a collapse.
Free tools Windows power users keep installed
One-click scans. No signup required.
That cluster matters: reducing narcolepsy to “people suddenly fall asleep” misses both its range and its effects on daily life. The National Institutes of Health overview describes symptoms and clinical evaluation. The U.S. FDA estimates that narcolepsy type 1 affects 1 in 2,000 people in the United States; that figure is specifically for type 1 and is an estimate, not a worldwide prevalence rate. (FDA, 5 August 2026)
#1 Best Overall
Why type 1 and type 2 are not interchangeable
The FDA describes narcolepsy type 1 as involving loss of orexin-producing brain cells. Orexin helps regulate wakefulness, sleep and muscle tone, which helps explain why disruption to its signaling can be associated with sleepiness and cataplexy. This mechanism should not be generalized to every person with narcolepsy: the approval described below is for type 1, not type 2.
How is narcolepsy diagnosed?
Diagnosis involves a clinician’s assessment, not a single home test. The NIH says an evaluation may include a clinical examination and medical and family history. A clinician may ask someone to keep a sleep journal for one to two weeks, recording sleep times and symptoms; the journal helps document patterns but does not diagnose narcolepsy.
Testing may include an overnight polysomnogram, which records sleep, followed by a multiple sleep latency test (MSLT) to assess how quickly a person falls asleep during scheduled daytime opportunities. These tests are performed in a sleep disorders clinic. A sleep journal can be a paper notebook, a digital note or another consistent record—the format does not replace clinical evaluation or testing. (NIH)
What is the new narcolepsy drug approved in 2026?
On 5 August 2026, the U.S. Food and Drug Administration approved Orzeyful (oveporexton) tablets for adults with narcolepsy type 1. The prescribing information identifies oveporexton as an orexin receptor 2 (OX2R) agonist: it acts on orexin signaling rather than only addressing an individual symptom. The FDA called it the first medicine approved for narcolepsy type 1 as a complete disorder and the first to directly target loss of orexin signaling. This is a U.S. approval; it does not establish authorization in other countries, approval for type 2, or use in children. (FDA announcement; FDA prescribing information)
Rank #3
What the FDA says the studies found
The FDA’s approval announcement summarizes two randomized, double-blind, placebo-controlled studies lasting 12 weeks and enrolling 273 adults. It reports improvements in ability to stay awake and patient-reported daytime sleepiness, fewer cataplexy episodes, and improvements in other symptoms. These are results reported by the FDA for the studied treatment period; they do not establish a cure or superiority over other medicines, since the announcement does not describe a head-to-head comparison.
Common side effects listed by the FDA include insomnia, increased urinary frequency, urgency to urinate and increased saliva production. The agency says safety and effectiveness have not been established for people under 18, and warns against taking oveporexton with strong CYP3A inhibitors. Patients should consult a clinician and the current official prescribing information for decisions about suitability, interactions and risks. (FDA announcement; FDA prescribing information)
Does oveporexton treat narcolepsy type 2?
The FDA approval described here is for adults with narcolepsy type 1 only. It should not be presented as an approved treatment for type 2, and the FDA’s explanation of lost orexin-producing brain cells applies to type 1. People with type 2 should discuss their diagnosis and available options with a clinician rather than assume this approval applies to them.
Does the new drug make existing narcolepsy care obsolete?
No. A treatment that targets orexin signaling changes the landscape for adult type 1 narcolepsy, but it does not make other care irrelevant. The NIH describes treatment as tailored to symptoms and often combining medicines with behavioral or lifestyle measures. Established symptom-directed approaches may still be part of care; the available FDA and NIH material does not support ranking treatments against one another or claiming that older options no longer help.
The podcast listing identifies Julie Flygare as a guest and founder of Project Sleep, but it is not a transcript. It can establish the episode’s subject and participants, not specific testimony or quotations from the conversation. The FDA’s Tiffany R. Farchione, M.D., Director of the Division of Psychiatry within the FDA’s Center for Drug Evaluation and Research, said in the 5 August announcement: “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.” That statement concerns type 1 and the FDA’s characterization of the approval.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
